Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Tregs epigenetically reprogrammed from autoreactive effector T cells mitigate established autoimmunity
Tyler R. Colson, James J. Cameron, Hayley I. Muendlein, Mei-An Nolan, Jamie L. Leiriao, James H. Kim, Alexander N. Poltorak, Xudong Li
Tyler R. Colson, James J. Cameron, Hayley I. Muendlein, Mei-An Nolan, Jamie L. Leiriao, James H. Kim, Alexander N. Poltorak, Xudong Li
View: Text | PDF
Research Article Immunology Inflammation

Tregs epigenetically reprogrammed from autoreactive effector T cells mitigate established autoimmunity

  • Text
  • PDF
Abstract

Reprogramming autoreactive CD4+ effector T (Teff) cells into immunosuppressive Tregs represents a promising strategy for treating established autoimmune diseases. However, the stability and function of such reprogrammed Tregs under inflammatory conditions remain unclear. Here, we show that demethylation of core Treg identity genes in Teff cells yields lineage-stable effector T cell reprogrammed Tregs (ER-Tregs). A single adoptive transfer of ER-Tregs not only prevents autoimmune neuroinflammation in mice when given before disease onset but also arrests its progression when administered after onset. Compared with Foxp3-overexpressing Teff cells, induced Tregs from naive precursors, and endogenous Tregs, ER-Tregs provide superior protection against autoimmune neuroinflammation. This enhanced efficacy stems from their inherited autoantigen specificity and selectively preserved effector cell transcriptional programs, which together bolster their fitness in inflammatory environments and enhance their suppressive capacity. Our results establish epigenetic reprogramming of autoreactive Teff cells as an effective approach to generate potent, stable Tregs for the treatment of refractory autoimmune conditions.

Authors

Tyler R. Colson, James J. Cameron, Hayley I. Muendlein, Mei-An Nolan, Jamie L. Leiriao, James H. Kim, Alexander N. Poltorak, Xudong Li

×

Figure 1

Epigenetic reprogramming of CD4+ Teff cells into Tregs.

Options: View larger image (or click on image) Download as PowerPoint
Epigenetic reprogramming of CD4+ Teff cells into Tregs.
(A) Flow cytomet...
(A) Flow cytometry of Foxp3-Thy1.1 induction in CD4+ Teff cells isolated from Foxp3Thy1.1 mice on day 7 following immunization with MOG/CFA and subsequently activated with anti-CD3/CD28 microbeads for 4 days under indicated conditions. Rest indicates resting Teff cells for 4 days prior to their activation. RA indicates retinoic acid. VC indicates vitamin C. (B) Schematic of epigenetic reprogramming of CD4+ Teff cells into ER-Tregs. (C) Flow cytometry of Foxp3-Thy1.1 expression in 1° and 2° ER-Tregs generated in the presence or absence of VC. (D) Flow cytometry of Foxp3-Thy1.1 expression in 1° and 2° ER-Tregs generated in the presence or absence of VC and subsequently restimulated for 3 days in the presence of IL-6. (E) Heatmaps of CpG demethylation patterns at specific loci in indicated cell types, analyzed with bisulfite-sequencing. Each bar represents a CpG site. Data are shown as mean ± SEM. **P < 0.01, ****P < 0.0001, 1-way ANOVA and Holm-Šídák test in A and D, and 2-way ANOVA in E.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts